Clinical Trial Update: Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

View source ↗

Summary

An Early Access Program for ibrutinib in relapsed or refractory chronic lymphocytic leukemia has been approved for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Janssen-Cilag Farmaceutica Ltda. | Conditions: B-cell Chronic Lymphocytic Leukemia | Status: APPROVED_FOR_MARKETING